Thirty-eight patients with residual or recurrent primary thyroid cancers which did not take up 1-131 were treated with external beam irradiation. Excluding 5 patients with malignant lymphoma, there were 23 patients with local disease and 10 with distant metastases. Doses ranged from 3,500 to 7,000 rads (35-70 Gy) among the 23 with local disease; local tumor control was achieved in 8. Six are alive and well 2-11 years later. External beam irradiation should be considered in locally advanced, incompletely resected, recurrent and metastatic thyroid malignancies of all histological types without 1-131 uptake. Reviewed are the age and sex distribution, histology, stage, extent of surgery, and dose and radiotherapy technique as they affect survival and patterns of failure.

No abstract

This study investigated dose to bone tissue in electron beam therapy. Measurements were made using films and thermoluminescent dosimeters in a polystyrene phantom containing bone inhomogeneity for 15-MeV, 12-MeV, and 9-MeV electron beams. An increase in dose of approximately 18%, 12%, and 11%, for the three electron energies respectively, relative to the dose in polystyrene, was found for bone material having an electron density (relative to water) of 1.73. Measurements were also made using films for 15- and 9-MeV electrons in a phantom with a mandibular bone and teeth. A dose enhancement in bone of approximately 10% and 7%, respectively, for the two energies was found in the phantom where the electron density of bone was about 1.60. These results suggest that injury to bone is possible in those clinical situations where high doses of electrons are used for therapy.

Twenty-four patients with biopsy-proved squamous-cell carcinoma of the penis underwent external-beam radiation therapy between 1966 and 1980. Fifteen were treated for the primary tumor and 9 for metastatic inguinal lymphadenopathy; no patient received prophylactic nodal irradiation. Doses ranged from 4,500 rad (45 Gy)/15 fractions/3 wk. to 6,400 rad (64 Gy)/32 fractions/6 1/2 wk. Seven out of 9 tumors in stage I, 2/3 in stage II, and 1/3 in stage IV were controlled for three years. Control of fixed, inoperable groin nodes was poor, and none of these patients survived beyond 1 1/2 years.

No abstract